Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncology

“We are moving toward a future where we have enough medications that each work individually and have minimal side effects so that we can create even larger combinations, which offer the most benefit to people,” said David Weinstock, vice president of discovery oncology at Merck, whose blockbuster immunotherapy Keytruda is a go-to for such combos.